PuSH - Publikationsserver des Helmholtz Zentrums München

von Schnurbein, J.* ; Heni, M.* ; Moss, A.* ; Nagel, S.A.* ; Machann, J. ; Muehleder, H.* ; Debatin, K.M.* ; Farooqi, S.* ; Wabitsch, M.*

Rapid improvement of hepatic steatosis after initiation of leptin substitution in a leptin-deficient girl.

Horm. Res. Paediatr. 79, 310-317 (2013)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Background: Leptin deficiency is associated with severe obesity and metabolic disturbances. Increased liver fat content has been reported in only one case beforehand, even though hepatic steatosis is a typical comorbidity of common obesity. It is also frequent in patients with lipodystrophy where it resolves under leptin therapy. Subject and Methods: In 2010, we reported a leptin-deficient patient with a novel homozygous mutation in the leptin gene and severe hepatic steatosis. We have now studied serum changes and changes in liver fat content during the substitution with recombinant methionyl human leptin. Results: After 23 weeks of leptin substitution, elevated transaminases, total cholesterol and low-density lipoprotein levels normalized. After 62 weeks, homeostasis model assessment of insulin resistance improved from 10.7 to 6.0 and body fat mass dropped from 50.2 to 37.8%. Liver fat content was drastically reduced from 49.7 to 9.4%. The first changes in liver fat content were detectable after 3 days of therapy. Conclusion: Our patient showed a remarkable reduction of liver fat content during the treatment with recombinant methionyl human leptin. These changes occurred rapidly after initiation of the substitution, which implies that leptin has a direct effect on hepatic lipid metabolism in humans as it is seen in rodents.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Leptin ; Obesity ; Hormone Replacement Therapy ; Insulin Resistance ; Non-alcoholic Fatty Liver Disease; Fatty Liver-disease ; Insulin-resistance ; Generalized Lipodystrophy ; Missense Mutation ; Receptor Gene ; Replacement Therapy ; Diabetes-mellitus ; Adipose-tissue ; Acid Oxidation ; Morbid-obesity
ISSN (print) / ISBN 1663-2818
e-ISSN 1663-2826
Quellenangaben Band: 79, Heft: 5, Seiten: 310-317 Artikelnummer: , Supplement: ,
Verlag Karger
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed